New classification for identifying HR myeloma based on cytogenetic abnormalities
Michael Hallek, MD, University Clinic of Cologne, Germany, and Workshop Chair of XV iwCLL 2013 in Cologne, 9-11 September, talks to ecancer at EHA about the upcoming iwCLL meeting and a number of topics in CLL that will be covered in the programme including molecular biology, cellular biology, prognostication, novel treatment approaches, stem cell transplantation, and optimising clinical trial design.
The 15th iwCLL will incorporate state of the art lectures from experts in the field plus presentations based on the best submitted abstracts. Expert speakers include Carlo M Croce, Stephan Stilgenhauer, Cathy Wu, John Gribben, Nicholas Chiorazzi, Kanti Rai, Neil Kay, William G Wierda, Tait Shanafelt, Michael J Keating, John C Byrd, Emili Montserrat, Peter Dreger, Peter Hillmen, Tadeusz Robak, Federico Caligaris-Cappio, Guillaume Dighiero and Tom Kipps.
There will also be a Young Investigators Meeting on CLL integrated into iwCLL on Sunday Sept 8 where young investigators will have the opportunity to share their research interests in CLL in a collaborative workshop setting.
For more information on XV iwCLL programme, registration and abstract submission visit:
http://www.iwcll2013.org/
New classification for identifying HR myeloma based on cytogenetic abnormalities
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Revolutionising myeloma treatment through immune profiling
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies